Verified factor-similar pair

BBSC vs SCHA

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
89
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • SCHA has the higher backtested relative Sharpe (0.906 vs 0.891).
  • SCHA has the lower published fee (0.04% vs 0.09%).
  • SCHA is cheaper on dividend valuation (133 vs 139, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

BBSC

JPMorgan BetaBuilders U.S. Small Cap Equity Fund
SMB
Adj. R2
0.986
Rel. Sharpe
0.891
Mkt beta
1.06
AUM
US$700M
MER
0.09%
Valuation
139

SCHA

Schwab U.S. Small-Cap ETF
SMB
Adj. R2
0.985
Rel. Sharpe
0.906
Mkt beta
1.03
AUM
US$21.0B
MER
0.04%
Valuation
133

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
BBSC
+0.95
|t|
+27.7
SCHA
+0.74
|t|
+34.7
diff +0.21
HML
BBSC
+0.05
|t|
+1.4
SCHA
+0.12
|t|
+5.8
diff -0.08
RMW
BBSC
-0.13
|t|
-3.8
SCHA
-0.08
|t|
-3.3
diff -0.05
CMA
BBSC
+0.06
|t|
+1.4
SCHA
-0.03
|t|
-0.8
diff +0.09
UMD
BBSC
+0.04
|t|
+1.5
SCHA
+0.05
|t|
+3.2
diff -0.01

Why This Pair Matches

Exposure level
86
Exposure shape
99
Mkt beta diff
0.03
Rel. Sharpe diff
0.015

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

BBSC fund page SCHA fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.